PHYTONADIONE, (E)-(±)-
Stroke
The George Institute for Global Health, ChinaSmall moleculeN/ADormant
D
28/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 65/ 100
Competitive context
141 Active assets in the Stroke cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivaroxaban China National Center for Cardiovascular Diseases | Phase 4 | BBB |
Tenecteplase Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
Acetylsalicylic Acid China National Center for Cardiovascular Diseases | Phase 4 | BB |
Ticagrelor Assistance Publique - Hôpitaux de Paris | Phase 4 | BB |
WARFARIN China National Center for Cardiovascular Diseases | Phase 4 | BB |
View all 50 →
Same molecule, other indications
PHYTONADIONE, (E)-(±)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →